Clinical Trial Update: A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia [Phase 2]

View source ↗

Summary

Phase IIb pilot study evaluating a modified dosing regimen of AMG0001 in subjects with critical limb ischemia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Arterial Disease

Drugs mentioned

• AMG0001

Snippet

Sponsor: AnGes USA, Inc. | Conditions: Critical Limb Ischemia, Vascular Diseases | Phase 2 | Status: COMPLETED | Results posted: 2021-01-22